Aktienanalyse zu Cryo-Cell International Inc (CCEL)CCELCryo-Cell International Inc

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Cryo-Cell International Inc is not a strong buy at the moment. The current price is $4.00, with a recent 5-day change of -12.28%, indicating significant short-term volatility. While the gross margin is relatively high at 76.07%, the company has reported a net income of only $47,000 in Q1 2026, down from $283,000 in Q1 2025, raising concerns about profitability. Additionally, the forward P/E ratio is extremely high at 2000, suggesting that the stock may be overvalued given its current earnings performance. The main risk is the compliance notice from NYSE American, which could lead to delisting if not resolved by September 2027. Therefore, it is advisable to hold off on purchasing until there is clearer evidence of recovery and compliance.